Trial Profile

Immune response and safety of AE 37 plus HER2/Neu GP2 vaccine in patients with breast and ovarian cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AE 37 (Primary) ; HER2/Neu GP2 vaccine Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology (Primary)
Indications Breast cancer; Ovarian cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

08 Aug 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com